WellDoc is a Baltimore, MD–based digital health technology company that develops mobile solutions to drive behavioral and clinical change in chronic disease. Led by CEO Kevin McRaith, the company has commercialized BlueStar, an FDA-cleared, reimbursable digital therapeutic and mobile prescription therapy for adults with type 2 diabetes. BlueStar is designed to fill the support gap between patients and providers when individuals are outside the healthcare system. WellDoc raised an additional $7.5M as an extension of its Series B, bringing the round to $29.5M. Johnson & Johnson Innovation and JJDC participated in the extension as part of a broader collaboration with LifeScan, Inc., a Johnson & Johnson Diabetes Care business. Under the collaboration, WellDoc plans to integrate BlueStar with LifeScan’s OneTouch Verio Flex Bluetooth Smart blood glucose monitor and the OneTouch Reveal mobile app. The partners intend to combine LifeScan’s monitoring systems and mobile app with WellDoc’s data analytics and patient engagement to create a real-time, personalized approach to managing type 2 diabetes. WellDoc commercializes BlueStar®, a prescription mobile therapy cleared by the U.S. FDA for adults with type 2 diabetes. BlueStar is powered by WellDoc’s Automated Expert Analytics System™ and provides real-time motivational, behavioral and educational coaching to enable patient self-management. The therapy requires a prescription from a licensed healthcare provider, can be dispensed by a pharmacy and may be reimbursed by health plans. Led by CEO Kevin McRaith, the company intends to use new funding to continue commercialization and accelerate adoption of BlueStar. The product positioning and regulatory clearance suggest a focus on payer and provider integration to drive uptake. No revenue or user metrics were disclosed in the article. WellDoc is a healthcare behavioral science and technology company whose flagship product is BlueStar, the first FDA-cleared mobile prescription therapy for adults with type 2 diabetes (cleared July 2010). BlueStar requires a prescription, can be dispensed and reimbursed through a pharmacy, and is powered by WellDoc’s proprietary Automated Expert Analytics System. The product delivers real-time motivational, behavioral and educational coaching to help patients self-manage diabetes and provides clinical decision support to healthcare providers to optimize treatment decisions. WellDoc says the new funding will help it launch and commercialize BlueStar on a nationwide basis. The company broadened its capitalization beyond an initial group of angel investors by taking on its first institutional backers. Forbes selected WellDoc as one of "America's Most Promising Companies." WellDoc, founded in 2005 and based in Baltimore, develops the BlueStar diabetes self-management platform and a prescription mobile therapy for Type 2 diabetes. The company put its flagship apps through clinical trials and sought 510(k) clearance, which helped earn physician confidence to prescribe the product. BlueStar is reimbursed by insurance for physician-prescribed use and is being offered to employees at Fortune 500 companies, including Ford Motor Company, Rite Aid, and DexCom. The app includes medication adherence tracking, real-time transmission and storage of blood-glucose levels, patient coaching, and analytics to highlight trends for clinicians. Management says reimbursement has been critical to growth and the company plans to roll out apps for other chronic conditions such as cardiovascular and respiratory care.

Total raised

$58M

Funding rounds

4

Latest round

Series B

Latest activity

Mar 2016